Loargys (pegzilarginase-nbln) Coverage Criteria
Customize your policy alerts
Sign up for Empire Bluecross Policy CC-0301 alerts
Get alerted when Policy CC-0301 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and medical-necessity review for Loargys, an enzyme replacement therapy for adults and children 2 years of age or older with Arginase 1 Deficiency. Coverage requires diagnostic verification, concurrent dietary protein restriction, and additional response documentation for continuation therapy.
New clinical criteria were established for initial and continuation coverage of Loargys.
A quantity limit was added for Loargys of 0.2 mg/kg once weekly.
HCPCS codes C9399 and J3590 and ICD-10-CM code E72.21 were added for Loargys-related billing and diagnosis coding.
Documentation requirements were added to support verification of Arginase 1 Deficiency.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.